Brief: Finch Therapeutics Presents PRISM-EXT biomarker Data At ACG 2022
24/10/2022 13:16
Oct 24 (Reuters) - Finch Therapeutics Group Inc
FNCH.O :
* FINCH THERAPEUTICS PRESENTS PRISM-EXT BIOMARKER DATA AT
ACG 2022
AND PROCEEDS WITH PATIENT DOSING IN PHASE 3 TRIAL OF CP101 IN
RECURRENT C. DIFFICILE INFECTION
Source text for Eikon: ID:nGNX3Y1NS2
Further company coverage: FNCH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp